Molecular Pathogenesis of Pancreatic Cancer

Annual Review of Genomics and Human Genetics

Volumn 4, Issue , 2003, Pages 237-256

  Hansel, Donna E ^a   Kern, Scott E ^a   Hruban, Ralph H ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Chromosome; Epigenetics; Gene; Mutation; Pancreas

Indexed keywords

CANCER CLASSIFICATION; CANCER GROWTH; CANCER INVASION; CANCER SCREENING; CANCER SURVIVAL; CHROMOSOME ABERRATION; GENE MUTATION; INHERITANCE; MOLECULAR BIOLOGY; PANCREAS CANCER; PANCREAS DUCT; PATHOGENESIS; POINT MUTATION; REVIEW; SURVIVAL RATE;

CHROMOSOME ABERRATIONS; DNA, MITOCHONDRIAL; GENE SILENCING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; PANCREATIC NEOPLASMS;

EID: 0242693286     PISSN: 15278204     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.genom.4.070802.110341     Document Type: Review

References (126)

1. Abraham SC, Klimstra DS, Wilentz RE, Yeo CJ, Conlon K, et al. 2002. Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations. Am. J. Pathol. 160:1361-69
2. Abraham SC, Wu TT, Hruban RH, Lee JH, Yeo CJ, et al. 2002. Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma: frequent allelic loss on chromosome 11p and alterations in the APC/beta-catenin pathway. Am. J. Pathol. 160:953-62
3. Abraham SC, Wu TT, Klimstra DS, Finn LS, Lee JH, et al. 2001. Distinctive molecular genetic alterations in sporadic and familial adenomatous polyposis-associated pancreatoblastomas: frequent alterations in the APC/beta-catenin pathway and chromosome 11p. Am. J. Pathol. 159:1619-27
4. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. 1988. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53:549-54
5. Argani-Donahue P, Iacobuzio C, Ryu B, Rosty C, Goggins M, et al. 2001. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin. Cancer Res. 7:3862-68
6. Armengol G, Capella G, Farre L, Peinado MA, Miro R, Caballin MR. 2001. Genetic evolution in the metastatic progression of human pancreatic cancer studied by CGH. Lab Invest. 81:1703-7
7. Artandi SE, Chang S, Lee SL, Alson S, Gottlieb GJ, et al. 2000. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 406:641-45
8. Bardeesy N, DePinho RA. 2002. Pancreatic cancer biology and genetics. Nat. Rev. Cancer 2:897-909
9. Bardi G, Johansson B, Pandis N, Mandahl N, Bak-Jensen E, et al. 1993. Karyotypic abnormalities in tumours of the pancreas. Br. J. Cancer 67:1106-12
10. Barton CM, Staddon SL, Hughes CM, Hall PA, O'Sullivan C, et al. 1991. Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br. J. Cancer 64:1076-82
11. Bartsch D, Shevlin DW, Tung WS, Kisker O, Wells SA Jr, Goodfellow PJ. 1995. Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas. Genes Chromosomes Cancer 14:189-95
12. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. 1998. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res. 72:141-96
13. Berman DB, Costalas J, Schultz DC, Grana G, Daly M, Godwin AK. 1996. A common mutation in BRCA2 that predisposes to a variety of cancers is found in both Jewish Ashkenazi and non-Jewish individuals. Cancer Res. 56:3409-14
14. Berrozpe G, Schaeffer J, Peinado MA, Real FX, Perucho M. 1994. Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer. Int. J. Cancer 58:185-91
15. Berthelemy P, Bouisson M, Escourrou J, Vaysse N, Rumeau JL, Pradayrol L. 1995. Identification of K-ras mutations in pancreatic juice in the early diagnosis of pancreatic cancer. Ann. Intern. Med. 123:188-91
16. Blasco MA, Rizen M, Greider CW, Hanahan D. 1996. Differential regulation of telomerase activity and telomerase RNA during multi-stage tumorigenesis. Nat. Genet. 12:200-4
17. Brat DJ, Hahn SA, Griffin CA, Yeo CJ, Kern SE, Hruban RH. 1997. The structural basis of molecular genetic deletions. An integration of classical cytogenetic and molecular analyses in pancreatic adenocarcinoma. Am. J. Pathol. 150:383-91
18. Brat DJ, Lillemoe KD, Yeo CJ, Warfield PB, Hruban RH. 1998. Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas. Am. J. Surg. Pathol. 22:163-69
19. Brentnall TA, Bronner MP, Byrd DR, Haggitt RC, Kimmey MB. 1999. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann. Intern. Med. 131:247-55
20. Brentnall TA, Chen R, Lee JG, Kimmey MB, Bronner MP, et al. 1995. Microsatellite instability and K-ras mutations associated with pancreatic adenocarcinoma and pancreatitis. Cancer Res. 55:4264-67
21. Brockie E, Anand A, Albores-Saavedra J. 1998. Progression of atypical ductal hyperplasia/carcinoma in situ of the pancreas to invasive adenocarcinoma. Ann. Diagn. Pathol. 2:286-92
22. Buchler P, Conejo-Garcia JR, Lehmann G, Muller M, Emrich T, et al. 2001. Real-time quantitative PCR of telomerase mRNA is useful for the differentiation of benign and malignant pancreatic disorders. Pancreas 22:331-40
23. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, et al. 1994. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat. Genet. 8:27-32
24. Caldas C, Hahn SA, Hruban RH, Redston MS, Yeo CJ, Kern SE. 1994. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res. 54:3568-73
25. Cohen JA, Weiner DB, More KF, Kokai Y, Williams WV, et al. 1989. Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (p185neu) in normal and transformed epithelial tissues of the digestive tract. Oncogene 4:81-88
26. Curtis LJ, Li Y, Gerbault-Seureau M, Kuick R, Dutrillaux AM, et al. 1998. Amplification of DNA sequences from chromosome 19q13.1 in human pancreatic cell lines. Genomics 53:42-55
27. Dat NM, Sontag SJ. 1982. Pancreatic carcinoma in brothers. Ann. Intern. Med. 97:282
28. Day JD, Digiuseppe JA, Yeo C, Lai-Goldman M, Anderson SM, et al. 1996. Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. Hum. Pathol. 27: 119-24
29. Eberle MA, Pfutzer R, Pogue-Geile KL, Bronner MP, Crispin D, et al. 2002. A new susceptibility locus for autosomal dominant pancreatic cancer maps to chromosome 4q32-34. Am. J. Hum. Genet. 70:1044-48
30. Ehrenthal D, Haeger L, Griffin T, Compton C. 1987. Familial pancreatic adenocarcinoma in three generations. A case report and a review of the literature. Cancer 59:1661-64
31. Esteller M, Catasus L, Matias-Guiu X, Mutter GL, Prat J, et al. 1999. hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis. Am. J. Pathol. 155:1767-72
32. Fernandez E, La Vecchia C, D'Avanzo B, Negri E, Franceschi S. 1994. Family history and the risk of liver, gallbladder, and pancreatic cancer. Cancer Epidemiol. Biomark. Prev. 3:209-12
33. Friess H, Kleeff J, Korc M, Buchler MW. 1999. Molecular aspects of pancreatic cancer and future perspectives. Dig. Surg. 16:281-90
34. Fukushige S, Furukawa T, Satoh K, Sunamura M, Kobari M, et al. 1998. Loss of chromosome 18q is an early event in pancreatic ductal tumorigenesis. Cancer Res. 58:4222-26
35. Fukushima N, Sato N, Ueki T, Rosty C, Walter KM, et al. 2002. Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma. Am. J. Pathol. 160:1573-81
36. Ghadimi BM, Schrock E, Walker RL, Wangsa D, Jauho A, et al. 1999. Specific chromosomal aberrations and amplification of the AIB1 nuclear receptor coactivator gene in pancreatic carcinomas. Am. J. Pathol. 154:525-36
37. Ghadirian P, Boyle P, Simard A, Baillargeon J, Maisonneuve P, Perret C. 1991. Reported family aggregation of pancreatic cancer within a population-based case-control study in the Francophone community in Montreal, Canada. Int. J. Pancreatol. 10:183-96
38. Giardiello FM, Welsh SB, Hamilton SR, Offerhaus GJ, Gittelsohn AM, et al. 1987. Increased risk of cancer in the Peutz-Jeghers syndrome. N. Engl. J. Med. 316:1511-14
39. Gisselsson D, Jonson T, Petersen A, Strombeck B, Dal Cin P, et al. 2001. Telomere dysfunction triggers extensive DNA fragmentation and evolution of complex chromosome abnormalities in human malignant tumors. Proc. Natl. Acad. Sci. USA 98:12683-88
40. Goggins M, Offerhaus GJ, Hilgers W, Griffin CA, Shekher M, et al. 1998. Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. Am. J. Pathol. 152:1501-7
41. Goggins M, Schutte M, Lu J, Moskaluk CA, Weinstein CL, et al. 1996. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res. 56:5360-64
42. Goldstein AM, Fraser MC, Struewing JP, Hussussian CJ, Ranade K, et al. 1995. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N. Engl. J. Med. 333:970-74
43. Gorunova L, Hoglund M, Andren-Sandberg A, Dawiskiba S, Jin Y, et al. 1998. Cytogenetic analysis of pancreatic carcinomas: intratumor heterogeneity and nonrandom pattern of chromosome aberrations. Genes Chromosomes Cancer 23:81-99
44. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. 2001. Cancer statistics, 2001. CA Cancer J. Clin. 51:15-36
45. Griffin CA, Hruban RH, Long PP, Morsberger LA, Douna-Issa F, Yeo CJ. 1994. Chromosome abnormalities in pancreatic adenocarcinoma. Genes Chromosomes Cancer 9:93-100
46. Griffin CA, Hruban RH, Morsberger LA, Ellingham T, Long PP, et al. 1995. Consistent chromosome abnormalities in adenocarcinoma of the pancreas. Cancer Res. 55:2394-99
47. Hackett JA, Greider CW. 2002. Balancing instability: dual roles for telomerase and telomere dysfunction in tumorigenesis. Oncogene 21:619-26
48. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, et al. 1996. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271:350-53
49. Han HJ, Yanagisawa A, Kato Y, Park JG, Nakamura Y. 1993. Genetic instability in pancreatic cancer and poorly differentiated type of gastric cancer. Cancer Res. 53:5087-89
50. Harley CB, Villeponteau B. 1995. Telomeres and telomerase in aging and cancer. Curr. Opin. Genet. Dev. 5:249-55
51. Heidenblad M, Jonson T, Mahlamaki EH, Gorunova L, Karhu R, et al. 2002. Detailed genomic mapping and expression analyses of 12p amplifications in pancreatic carcinomas reveal a 3.5-Mb target region for amplification. Genes Chromosomes Cancer 34:211-23
52. Hempen PM, Zhang L, Bansal RK, Iacobuzio-Donahue CA, Murphy KM, et al. 2003. Evidence of selection for clones having genetic inactivation of the activin A type II receptor gene in gastrointestinal cancers. Cancer Res. 63:994-99
53. Hoglund M, Gorunova L, AndrenSandberg A, Dawiskiba S, Mitelman F, Johansson B. 1998. Cytogenetic and fluorescence in situ hybridization analyses of chromosome 19 aberrations in pancreatic carcinomas:frequent loss of 19p13.3 and gain of 19q13.1-13.2. Genes Chromosomes Cancer 21:8-16
54. Hoorens A, Lemoine NR, McLellan E, Morohoshi T, Kamisawa T, et al. 1993. Pancreatic acinar cell carcinoma. An analysis of cell lineage markers, p53 expression, and Ki-ras mutation. Am. J. Pathol. 143:685-98
55. Hoorens A, Prenzel K, Lemoine NR, Kloppel G. 1998. Undifferentiated carcinoma of the pancreas: analysis of intermediate filament profile and Ki-ras mutations provides evidence of a ductal origin. J. Pathol. 185:53-60
56. Hruban RH, Goggins M, Parsons J, Kern SE. 2000. Progression model for pancreatic cancer. Clin. Cancer Res. 6:2969-72
57. Hruban RH, Iacobuzio-Donahue C, Wilentz RE, Goggins M, Kern SE. 2001. Molecular pathology of pancreatic cancer. Cancer J. 7:251-58
58. Hruban RH, van Mansfeld AD, Offerhaus GJ, van Weering DH, Allison DC, et al. 1993. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am. J. Pathol. 143:545-54
59. Hruban RH, Wilentz RE, Goggins M, Offerhaus GJ, Yeo CJ, Kern SE. 1999. Pathology of incipient pancreatic cancer. Ann. Oncol. 10 Suppl. 4:9-11
60. Hruban RH, Wilentz RE, Kern SE. 2000. Genetic progression in the pancreatic ducts. Am. J. Pathol. 156:1821-25
61. Iacobuzio-Donahue CA, Ryu B, Hruban RH, Kern SE. 2002. Exploring the host desmoplastic response to pancreatic carcinoma: gene expression of stromal and neoplastic cells at the site of primary invasion. Am. J. Pathol. 160:91-99
62. Jones JB, Song JJ, Hempen PM, Parmigiani G, Hruban RH, Kern SE. 2001. Detection of mitochondrial DNA mutations in pancreatic cancer offers a "mass"-ive advantage over detection of nuclear DNA mutations. Cancer Res. 61:1299-304
63. Kang GH, Shim YH, Jung HY, Kim WH, Ro JY, Rhyu MG. 2001. CpG island methylation in premalignant stages of gastric carcinoma. Cancer Res. 61:2847-51
64. Katkhouda N, Mouiel J. 1986. Pancreatic cancer in mother and daughter. Lancet 2:747
65. Kattwinkel J, Lapey A, Di Sant'Agnese PA, Edwards WA. 1973. Hereditary pancreatitis:three new kindreds and a critical review of the literature. Pediatrics 51:55-69
66. Kern SE, Hruban RH, Hidalgo M, Yeo CJ. 2002. An introduction to pancreatic adenocarcinoma genetics, pathology, and therapy. Cancer Biol. 1:607-13
67. Kinzler KW, Vogelstein B. 1996. Lessons from hereditary colorectal cancer. Cell 87:159-70
68. Kleeff J, Fukahi K, Lopez ME, Friess H, Buchler MW, et al. 2002. Targeting of suicide gene delivery in pancreatic cancer cells via FGF receptors. Cancer Gene Therap. 9:522-32
69. Klein AP, Beaty TH, Bailey-Wilson JE, Brune KA, Hruban RH, Petersen GM. 2002. Evidence for a major gene influencing risk of pancreatic cancer. Genet. Epidemiol. 23:133-49
70. Kobitsu K, Tsutsumi M, Tsujiuchi T, Suzuki F, Kido A, et al. 1997. Shortened telomere length and increased telomerase activity in hamster pancreatic duct adenocarcinomas and cell lines. Mol. Carcinog. 18:153-59
71. Korc M. 1998. Role of growth factors in pancreatic cancer. Surg. Oncol. Clin. North Am. 7:25-41
72. Lemoine NR, Jain S, Hughes CM, Staddon SL, Maillet B, et al. 1992. Ki-ras oncogene activation in preinvasive pancreatic cancer. Gastroenterology 102: 230-36
73. Levin DL, Connelly RR, Devesa SS. 1981. Demographic characteristics of cancer of the pancreas: mortality, incidence, and survival. Cancer 47:1456-68
74. Lumadue JA, Griffin CA, Osman M, Hruban RH. 1995. Familial pancreatic cancer and the genetics of pancreatic cancer. Surg. Clin. N. Am. 75:845-55
75. Luo J, Guo P, Matsuda K, Truong N, Lee A, et al. 2001. Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo. Int. J. Cancer 92:361-69
76. Luttges J, Schlehe B, Menke MA, Vogel I, Henne-Bruns D, Kloppel G. 1999. The K-ras mutation pattern in pancreatic ductal adenocarcinoma usually is identical to that in associated normal, hyperplastic, and metaplastic ductal epithelium. Cancer 85:1703-10
77. Lynch HT, Brand RE, Deters CA, Shaw TG, Lynch JF. 2001. Hereditary pancreatic cancer. Pancreatology 1:466-71
78. Lynch HT, Fusaro RM. 1991. Pancreatic cancer and the familial atypical multiple mole melanoma (FAMMM) syndrome. Pancreas 6:127-31
79. Lynch HT, Smyrk TC, Watson P, Lanspa SJ, Lynch JF, et al. 1993. Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer:an updated review. Gastroenterology 104:1535-49
80. Mahlamaki EH, Hoglund M, Gorunova L, Karhu R, Dawiskiba S, et al. 1997. Comparative genomic hybridization reveals frequent gains of 20q, 8q, 11q, 12p, and 17q, and losses of 18q, 9p, and 15q in pancreatic cancer. Genes Chromosomes Cancer 20:383-91
81. Massague J, Blain SW, Lo RS. 2000. TGFβ signaling in growth control, cancer, and heritable disorders. Cell 103:295-309
82. Moskaluk CA, Hruban RH, Kern SE. 1997. p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res. 57:2140-43
83. Murphy KM, Brune KA, Griffin C, Sollenberger JE, Petersen GM, et al. 2002. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res. 62:3789-93
84. O'Hagan RC, Chang S, Maser RS, Mohan R, Artandi SE, et al. 2002. Telomere dysfunction provokes regional amplification and deletion in cancer genomes. Cancer Cell 2:149-55
85. Pellegata NS, Sessa F, Renault B, Bonato M, Leone BE, et al. 1994. K-ras and p53 gene mutations in pancreatic cancer:ductal and nonductal tumors progress through different genetic lesions. Cancer Res. 54:1556-60
86. Redston MS, Caldas C, Seymour AB, Hruban RH, da Costa L, et al. 1994. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res. 54:3025-33
87. Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, et al. 1997. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res. 57:1731-34
88. Ruggeri B, Zhang SY, Caamano J, DiRado M, Flynn SD, Klein-Szanto AJ. 1992. Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes. Oncogene 7:1503-11
89. Ruggeri BA, Huang L, Wood M, Cheng JQ, Testa JR. 1998. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol. Carcinog. 21:81-86
90. Russo AA, Tong L, Lee JO, Jeffrey PD, Pavletich NP. 1998. Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a. Nature 395:237-43
91. Satoh K, Sawai T, Shimosegawa T, Koizumi M, Yamazaki T, et al. 1993. The point mutation of c-Ki-ras at codon 12 in carcinoma of the pancreatic head region and in intraductal mucin-hypersecreting neoplasm of the pancreas. Int. J. Pancreatol. 14:135-43
92. Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, et al. 1995. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268:1749-53
93. Scarpa A, Capelli P, Villaneuva A, Zamboni G, Lluis F, et al. 1994. Pancreatic cancer in Europe: Ki-ras gene mutation pattern shows geographical differences. Int. J. Cancer 57:167-71
94. Scarpa A, Capelli P, Zamboni G, Oda T, Mukai K, et al. 1993. Neoplasia of the ampulla of Vater. Ki-ras and p53 mutations. Am. J. Pathol. 142:1163-72
95. Schleger C, Arens N, Zentgraf H, Bleyl U, Verbeke C. 2000. Identification of frequent chromosomal aberrations in ductal adenocarcinoma of the pancreas by comparative genomic hybridization (CGH). J. Pathol. 191:27-32
96. Schutte M, da Costa LT, Hahn SA, Moskaluk C, Hoque AT, et al. 1995. Identification by representational difference analysis of a homozygous deletion in pancreatic carcinoma that lies within the BRCA2 region. Proc. Natl. Acad. Sci. USA 92:5950-54
97. Schutte M, Hruban RH, Geradts J, Maynard R, Hilgers W, et al. 1997. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res. 57:3126-30
98. Sellers WR, Rodgers JW, Kaelin WG Jr. 1995. A potent transrepression domain in the retinoblastoma protein induces a cell cycle arrest when bound to E2F sites. Proc. Natl. Acad. Sci. USA 92:11544-48
99. Sessa F, Solcia E, Capella C, Bonato M, Scarpa A, et al. 1994. Intraductal papillary-mucinous tumours represent a distinct group of pancreatic neoplasms: an investigation of tumour cell differentiation and K-ras, p53 and c-erbB-2 abnormalities in 26 patients. Virchows Arch. 425:357-67
100. Seymour AB, Hruban RH, Redston M, Caldas C, Powell SM, et al. 1994. Allelotype of pancreatic adenocarcinoma. Cancer Res. 54:2761-64
101. Smit VT, Boot AJ, Smits AM, Fleuren GJ, Cornelisse CJ, Bos JL. 1988. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res. 16:7773-82
102. Tada M, Ohashi M, Shiratori Y, Okudaira T, Komatsu Y, et al. 1996. Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease. Gastroenterology 110:227-31
103. Tada M, Omata M, Kawai S, Saisho H, Ohto M, et al. 1993. Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. Cancer Res. 53:2472-74
104. Tada M, Omata M, Ohto M. 1991. Ras gene mutations in intraductal papillary neoplasms of the pancreas. Analysis in five cases. Cancer 67:634-37
105. Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, et al. 1996. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat. Genet. 12:333-37
106. Taylor WR, Stark GR. 2001. Regulation of the G2/M transition by p53. Oncogene 20:1803-15
107. Terhune PG, Phifer DM, Tosteson TD, Longnecker DS. 1998. K-ras mutation in focal proliferative lesions of human pancreas. Cancer Epidemiol. Biomark. Prev. 7:515-21
108. Tersmette AC, Petersen GM, Offerhaus GJ, Falatko FC, Brune KA, et al. 2001. Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin. Cancer Res. 7:738-44
109. Tomaszewska R, Okon K, Nowak K, Stachura J. 1998. HER-2/Neu expression as a progression marker in pancreatic intraepithelial neoplasia. Pol. J. Pathol. 49:83-92
110. Ueki T, Toyota M, Skinner H, Walter KM, Yeo CJ, et al. 2001. Identification and characterization of differentially methylated CpG islands in pancreatic carcinoma. Cancer Res. 61:8540-46
111. Ueki T, Toyota M, Sohn T, Yeo CJ, Issa JP, et al. 2000. Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res. 60:1835-39
112. Umbricht CB, Evron E, Gabrielson E, Ferguson A, Marks J, Sukumar S. 2001. Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. Oncogene 20:3348-53
113. van Heek NT, Meeker AK, Kern SE, Yeo CJ, Lillemoe KD, et al. 2002. Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am. J. Pathol. 161:1541-47
114. Virmani AK, Muller C, Rathi A, Zoechbauer-Mueller S, Mathis M, Gazdar AF. 2001. Aberrant methylation during cervical carcinogenesis. Clin. Cancer Res. 7:584-89
115. Wallrapp C, Muller-Pillasch F, Solinas-Toldo S, Lichter P, Friess H, et al. 1997. Characterization of a high copy number amplification at 6q24 in pancreatic cancer identifies c-myb as a candidate oncogene. Cancer Res. 57:3135-39
116. Westra WH, Sturm P, Drillenburg P, Choti MA, Klimstra DS, et al. 1998. K-ras oncogene mutations in osteoclast-like giant cell tumors of the pancreas and liver: genetic evidence to support origin from the duct epithelium. Am. J. Surg. Pathol. 22:1247-54
117. Whelan AJ, Bartsch D, Goodfellow PJ. 1995. Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N. Engl. J. Med. 333:975-77
118. Wilentz RE, Chung CH, Sturm PD, Musler A, Sohn TA, et al. 1998. K-ras mutations in the duodenal fluid of patients with pancreatic carcinoma. Cancer 82:96-103
119. Wilentz RE, Goggins M, Redston M, Marcus VA, Adsay NV, et al. 2000. Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: a newly described and characterized entity. Am. J. Pathol. 156:1641-51
120. Wilentz RE, Hruban RH. 1998. Pathology of cancer of the pancreas. Surg. Oncol. Clin. N. Am. 7:43-65
121. Wilentz RE, Iacobuzio-Donahue CA, Argani P, McCarthy DM, Parsons JL, et al. 2000. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res. 60: 2002-6
122. Yamamoto H, Itoh F, Nakamura H, Fukushima H, Sasaki S, et al. 2001. Genetic and clinical features of human pancreatic ductal adenocarcinomas with widespread microsatellite instability. Cancer Res. 61:3139-44
123. Yamanaka Y, Friess H, Kobrin MS, Buchler M, Kunz J, et al. 1993. Overexpression of HER2/neu oncogene in human pancreatic carcinoma. Hum. Pathol. 24:1127-34
124. Yanagisawa A, Kato Y, Ohtake K, Kitagawa T, Ohashi K, et al. 1991. c-Ki-ras point mutations in ductectatic-type mucinous cystic neoplasms of the pancreas. Jpn. J. Cancer Res. 82:1057-60
125. Zhu Z, Kleeff J, Kayed H, Wang L, Korc M, et al. 2002. Nerve growth factor and enhancement of proliferation, invasion, and tumorigenicity of pancreatic cancer cells. Mol. Carcinog. 35:138-47
126. Lowenfels AB, Maisonneuve P, DiMagno EP, Elitsur Y, Gates LK Jr., et al. 1997. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J. Natl. Cancer Inst. 89:442-46